The current invention lacks specificity regarding preferred embodiments, potentially limiting its applicability and clarity in defining its scope.
The present invention offers a composition incorporating specific compounds and carriers, aiming to inhibit pancreatic lipase effectively.
The invention introduces novel compounds represented by Formula I, offering diverse substituent options to enhance pancreatic lipase inhibition efficacy.
Potential Indian Clients: Pharmaceutical companies, healthcare institutions focusing on obesity management
Current TRL: NA
Funded by: NA
IPC: A61K, C07D
Domain: Pharmaceutical Development for Obesity Treatment
This website uses cookies or similar technologies, to enhance your browsing experience.